Eli Lilly and Company (NYSE:LLY) Shares Acquired by Chris Bulman Inc

Chris Bulman Inc lifted its stake in Eli Lilly and Company (NYSE:LLY) by 36.2% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 369 shares of the company’s stock after acquiring an additional 98 shares during the quarter. Chris Bulman Inc’s holdings in Eli Lilly and Company were worth $327,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in LLY. Sovereign Financial Group Inc. grew its stake in shares of Eli Lilly and Company by 9.6% in the first quarter. Sovereign Financial Group Inc. now owns 671 shares of the company’s stock valued at $522,000 after buying an additional 59 shares in the last quarter. Wealthcare Advisory Partners LLC increased its stake in Eli Lilly and Company by 37.3% during the first quarter. Wealthcare Advisory Partners LLC now owns 8,834 shares of the company’s stock worth $6,873,000 after purchasing an additional 2,400 shares during the period. Sandbox Financial Partners LLC increased its stake in Eli Lilly and Company by 54.8% during the first quarter. Sandbox Financial Partners LLC now owns 3,427 shares of the company’s stock worth $2,666,000 after purchasing an additional 1,213 shares during the period. Signet Financial Management LLC lifted its position in shares of Eli Lilly and Company by 1.6% during the first quarter. Signet Financial Management LLC now owns 10,635 shares of the company’s stock worth $8,274,000 after purchasing an additional 168 shares in the last quarter. Finally, Janiczek Wealth Management LLC boosted its stake in shares of Eli Lilly and Company by 10.9% in the first quarter. Janiczek Wealth Management LLC now owns 1,267 shares of the company’s stock valued at $986,000 after purchasing an additional 125 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on LLY. Barclays increased their target price on shares of Eli Lilly and Company from $913.00 to $1,025.00 and gave the stock an “overweight” rating in a report on Wednesday, July 10th. Sanford C. Bernstein initiated coverage on Eli Lilly and Company in a research note on Thursday, October 17th. They issued an “outperform” rating and a $1,100.00 price objective on the stock. Berenberg Bank boosted their target price on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a research note on Wednesday, August 14th. Bank of America lifted their price objective on Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Finally, Guggenheim upped their target price on shares of Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a research note on Friday, August 16th. Three investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $1,002.24.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock opened at $902.96 on Thursday. The firm’s fifty day simple moving average is $921.12 and its 200-day simple moving average is $860.74. Eli Lilly and Company has a 12 month low of $547.61 and a 12 month high of $972.53. The stock has a market capitalization of $858.18 billion, a price-to-earnings ratio of 132.98, a PEG ratio of 2.79 and a beta of 0.42. The company has a debt-to-equity ratio of 1.74, a current ratio of 1.11 and a quick ratio of 0.87.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, August 8th. The company reported $3.92 EPS for the quarter, beating analysts’ consensus estimates of $2.64 by $1.28. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. The company had revenue of $11.30 billion for the quarter, compared to analyst estimates of $9.83 billion. As a group, equities analysts forecast that Eli Lilly and Company will post 16.49 earnings per share for the current year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.